When I was 39 years old, my life changed in an instant. I was a father of two young children, my daughter was six and my son almost six months…
As reported on News-Medical, an experimental treatment for idiopathic pulmonary fibrosis (IPF), rentosertib, was associated with shifts toward younger biological age profiles across multiple protein-based aging measures in a phase…
As reported on PharmaBiz, the U.S. Food and Drug Administration has accepted Takeda’s New Drug Application for the investigational oral therapy zasocitinib (TAK-279) and assigned the filing Priority Review status…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
